MedImmune collaborates with BioWa
US company MedImmune and BioWa, a US subsidiary of Japan's Kyowa Hakko Kogyo, have entered into a licensing and collaboration agreement to develop and commercialize new inflammatory disease therapies targeting the interleukin-5 receptor. Initially, they will focus on developing BIW-8405, a monoclonal antibody currently in Phase I clinical studies in patients with asthma.
BIW-8405 has been developed utilizing BioWa's POTELLIGENT technology platform for the development of antibody-dependent cellular cytotoxicity-enhanced antibodies. The molecule aims to directly deplete eosinophils, a class of white blood cells implicated in the pathology of asthma and other inflammatory diseases. Additionally, BIW-8405 has the potential to neutralize the activity of IL-5, which is believed to play a key role in the growth and development of eosinophils.
Under the terms of the deal, BioWa will receive an undisclosed upfront payment, milestones and royalties on future marketed products. It will have exclusive rights to the product in Japan and certain other Asian countries, while MedImmune will have them for the USA, Europe and all other markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze